advertisement
Abstract #8953 Published in IGR 5-2
Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination
Konstas AG; Papapanos P; Tersis I; Houliara D; Stewart WCOphthalmology 2003; 110: 1357-1360
PURPOSE: To evaluate the efficacy and safety of commercially available latanoprost 0.005% given every evening versus timolol 0.5% and dorzolamide 2% fixed combination (TDFC) given twice daily to white Greeks with primary open-angle glaucoma (POAG) and ocular hypertensive (OH) patients. DESIGN: A single-masked, two-center, crossover comparison with two six-week treatment periods occurring after at least a three-week medicine-free period. Diurnal curve intraocular pressure (IOP) was taken at 2.00, 6.00, and 10.00 a.m., and 2.00, 6.00, and 10.00 p.m. PARTICIPANTS: Thirty-four subjects with POAG or OH were enrolled. INTERVENTIONS: Latanoprost 0.005% given every evening and TDFC twice daily. MAIN OUTCOME MEASURES: The primary efficacy variable was diurnal IOP. RESULTS: Thirty-three patients completed the study. On the last day of treatment, the mean diurnal IOP pressure for latanoprost was 15.9 ± 2.3 mmHg and for TDFC was 15.3 ± 2.0 mmHg (p = 0.05). Individual time points for IOP were not statistically different between groups except at the 10.00 p.m. time point, when the mean for TDFC was 14.6 ± 2.7 mmHg and for latanoprost was 16.6 ± 3.1 mmHg (p < 0.006). Eighteen patients overall preferred latanoprost, versus two patients the fixed combination, generally because of the greater convenience of once daily dosing. Adverse events were not significantly different between groups except that a bitter taste was found more frequently with TDFC (n = 9) than with latanoprost (n = 0; p = 0.009). Despite screening to exclude intolerance to beta-blockers, a single patient had to discontinue the TDFC because of new-onset asthma. CONCLUSIONS: This study indicates that the 24-hour diurnal IOP is lowered more, by a small but statistically significant amount, with TDFC compared with latanoprost in POAG and OH patients.
Dr. A.G. Konstas, University Department of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
